Literature DB >> 29468408

Is ICER NICEr?

Deborah Freund1, Jennifer Choi2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29468408     DOI： 10.1007/s40273-018-0617-6

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  4 in total

1.  ICER's Revised Value Assessment Framework for 2017-2019: A Critique.

Authors:  Peter J Neumann; Joshua T Cohen
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981

2.  Defining Value: The Need for a Longer, Broader View.

Authors:  Tomas J Philipson; Sachin Kamal-Bahl; Anupam B Jena
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

3.  Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System?

Authors:  Alan Lyles
Journal:  Pharmacoeconomics       Date:  2017-05       Impact factor: 4.981

Review 4.  National trends in prescription drug expenditures and projections for 2016.

Authors:  Glen T Schumock; Edward C Li; Katie J Suda; Michelle D Wiest; JoAnn Stubbings; Linda M Matusiak; Robert J Hunkler; Lee C Vermeulen
Journal:  Am J Health Syst Pharm       Date:  2016-05-11       Impact factor: 2.637
  4 in total
  1 in total

1.  Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports.

Authors:  Jean A Gerlach; Brian Snow; Katherine M Prioli; Ronald Vertsman; Julie Patterson; Laura T Pizzi
Journal:  Am Health Drug Benefits       Date:  2020-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.